GLP-1 RAs linked to eye complications in JAMA case series
Researchers say the rapid correction of hyperglycaemia induced by the drugs might be to blame.
A case series has rekindled concerns about potential eye-related complications associated with semaglutide and tirzepatide.
Published in JAMA Ophthalmology, it documents instances of serious ophthalmic conditions, including non-arteritic anterior ischaemic optic neuropathy (NAION), bilateral papillitis and paracentral acute middle maculopathy (PAMM) in patients taking the medications.
The nine patients, aged between 37 and 77, were prescribed either semaglutide or tirzepatide for diabetes or weight loss.
The authors, led by the University of Utah’s Professor Bradley Katz, said seven patients developed NAION, which affects the optic nerve and can lead to sudden vision loss.
